Holmium-166 Microsphere Radioembolization of Hepatic Malignancies
- PMID: 30954190
- DOI: 10.1053/j.semnuclmed.2019.01.008
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies
Abstract
Holmium microspheres have recently become available in the European market as the third type of microspheres for radioembolization of unresectable liver malignancies. Holmium microspheres come with a dedicated administration system, and since these microspheres contain holmium-166 (166Ho) instead of yttrium-90, unique dosing and imaging possibilities have become available as well. In addition, a scout dose of 166Ho microspheres (Conformité Européenne mark is now granted and not pending anymore) can be used instead of 99mTc-macroaggragated albumin during the preparatory angiography procedure. So far, two prospective phase I and phase II clinical studies have been performed on 166Ho radioembolization in a population of liver metastases from mixed origins. These studies showed that a mean whole-liver dose of 60 Gy is safe and induces tumor response. Ongoing trials investigate the effect of 166Ho radioembolization in patients with neuroendocrine tumor metastases, hepatocellular carcinoma, and colorectal cancer metastases. Data derived from these studies will be used to refine the dosing schedule of 60 Gy to the whole liver and determine the optimal level of activity for each patient. This paper discusses several basics and provides an overview of relevant dosing aspects, technical aspects of performing holmium radioembolization, as well as a summary of completed and ongoing clinical studies and the upcoming developments regarding these microspheres.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study.J Nucl Med. 2018 Apr;59(4):582-588. doi: 10.2967/jnumed.117.197194. Epub 2017 Sep 15. J Nucl Med. 2018. PMID: 28916623 Clinical Trial.
-
Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.J Nucl Med. 2015 Jun;56(6):817-23. doi: 10.2967/jnumed.115.155564. Epub 2015 Apr 30. J Nucl Med. 2015. PMID: 25931477
-
(⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75. doi: 10.1007/s00259-014-2784-9. Epub 2014 May 13. Eur J Nucl Med Mol Imaging. 2014. PMID: 24819055 Clinical Trial.
-
Holmium-166 Radioembolization: Current Status and Future Prospective.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1634-1645. doi: 10.1007/s00270-022-03187-y. Epub 2022 Jun 21. Cardiovasc Intervent Radiol. 2022. PMID: 35729423 Free PMC article. Review.
-
Microsphere radioembolization of liver malignancies: current developments.Q J Nucl Med Mol Imaging. 2009 Jun;53(3):325-35. Q J Nucl Med Mol Imaging. 2009. PMID: 19521312 Review.
Cited by
-
Nano-radiopharmaceuticals as therapeutic agents.Front Med (Lausanne). 2024 Mar 15;11:1355058. doi: 10.3389/fmed.2024.1355058. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38560384 Free PMC article. Review.
-
Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies?World J Hepatol. 2023 Dec 27;15(12):1284-1293. doi: 10.4254/wjh.v15.i12.1284. World J Hepatol. 2023. PMID: 38223418 Free PMC article. Review.
-
MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors.Eur J Nucl Med Mol Imaging. 2024 May;51(6):1506-1515. doi: 10.1007/s00259-023-06567-9. Epub 2023 Dec 29. Eur J Nucl Med Mol Imaging. 2024. PMID: 38155237
-
Transarterial Radioembolization: Overview of Radioembolic Devices.Semin Intervent Radiol. 2023 Nov 2;40(5):461-466. doi: 10.1055/s-0043-1772814. eCollection 2023 Oct. Semin Intervent Radiol. 2023. PMID: 37927522 Review. No abstract available.
-
Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series.Cancers (Basel). 2023 Sep 29;15(19):4791. doi: 10.3390/cancers15194791. Cancers (Basel). 2023. PMID: 37835485 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical